Role Definition
| Field | Value |
|---|---|
| Job Title | Gynecologic Oncologist (SOC 29-1218 split / SGO subspecialty) |
| Seniority Level | Mid-to-Senior (5-15+ years post-fellowship, independent practice) |
| Primary Function | Fellowship-trained OB/GYN subspecialist who manages the full spectrum of gynecological cancers — ovarian, uterine/endometrial, cervical, vulvar, vaginal, and gestational trophoblastic disease. Performs complex radical surgery (cytoreductive/debulking surgery, radical hysterectomy, pelvic exenteration, pelvic/para-aortic lymphadenectomy, omentectomy, bowel resection) AND manages systemic chemotherapy, immunotherapy, PARP inhibitors, and targeted therapies. Leads multidisciplinary tumour boards, determines surgical candidacy vs palliative pathways, and manages patients through diagnosis, treatment, recurrence, and end-of-life. |
| What This Role Is NOT | NOT a general OB/GYN (parent role, 68.6 AIJRI) who delivers babies and manages routine gynecological care. NOT a medical oncologist (non-surgical, manages systemic therapy only). NOT a radiation oncologist. NOT a gynecological surgeon without oncology fellowship training. |
| Typical Experience | 12+ years post-medical school. MD/DO + 4-year OB/GYN residency + 3-4 year gynecologic oncology fellowship + ABOG board certification + subspecialty certification. DEA registration + state medical licence. |
Seniority note: Junior gynecologic oncologists (early post-fellowship) perform the same surgical and chemotherapy management under lighter caseloads — equally AI-resistant. The surgical and medical oncology core anchors the score regardless of seniority within the subspecialty.
Protective Principles + AI Growth Correlation
| Principle | Score (0-3) | Rationale |
|---|---|---|
| Embodied Physicality | 3 | Core surgical work in unstructured, variable anatomy. Every cancer is different — tumour size, adhesion patterns, bowel/bladder/vascular involvement vary unpredictably. Pelvic exenteration and cytoreductive debulking are among the most complex abdominal surgeries in medicine, requiring real-time tactile feedback and intraoperative decision-making in cramped pelvic spaces. |
| Deep Interpersonal Connection | 2 | Delivers cancer diagnoses, discusses radical surgery options (including organ sacrifice — colostomy, urostomy), navigates goals-of-care conversations when cure is no longer possible, and supports patients through recurrence and end-of-life transitions. Significant but less continuous than primary oncology nursing relationship. |
| Goal-Setting & Moral Judgment | 3 | Determines surgical candidacy (operate vs palliate), selects chemotherapy regimens, decides intraoperatively whether complete cytoreduction is achievable or futile, makes organ-sacrificing decisions during pelvic exenteration (3-5% operative mortality), and bears personal accountability for outcomes. Defines what SHOULD be done, not just what CAN be done. |
| Protective Total | 8/9 | |
| AI Growth Correlation | 0 | Demand driven by cancer incidence (rising with aging population, endometrial cancer rising with obesity epidemic, HPV-related cervical cancers), not AI adoption. |
Quick screen result: Protective 8/9 = Strong Green Zone signal. Proceed to confirm.
Task Decomposition (Agentic AI Scoring)
| Task | Time % | Score (1-5) | Weighted | Aug/Disp | Rationale |
|---|---|---|---|---|---|
| Complex cancer surgery (cytoreductive/debulking, radical hysterectomy, pelvic exenteration, lymphadenectomy, omentectomy, bowel resection) | 35% | 1 | 0.35 | NOT INVOLVED | Irreducible surgical complexity in variable tumour anatomy. Every debulking is different — adhesion patterns, vascular proximity, bowel involvement, retroperitoneal disease. da Vinci robotic-assisted surgery is Level 0 autonomy (surgeon-controlled tool). No autonomous surgical capability exists or is projected. Intraoperative decisions — whether to attempt complete cytoreduction, when to convert, where to resect — require real-time tactile and visual judgment. |
| Pre-operative assessment & surgical planning (imaging review, staging, MDT tumour board, candidacy determination) | 15% | 2 | 0.30 | AUGMENTATION | AI-integrated 3D surgical planning from CT/MRI/PET is in early research. AI biomarker tools (MIA3G for ovarian cancer risk) augment staging. Surgeon still interprets imaging in clinical context, determines operability, and makes the operate-vs-palliate decision. |
| Chemotherapy/immunotherapy management (regimen selection, dose adjustment, PARP inhibitor management, toxicity monitoring) | 15% | 2 | 0.30 | AUGMENTATION | Clinical decision support tools help match patients to regimens based on genomic profiles (Tempus, Foundation Medicine). Surgeon-oncologist still selects regimens, manages dose modifications for toxicity, monitors treatment response, and decides when to switch lines of therapy. Licensed prescribing authority required. |
| Post-operative care & complication management (wound care, stoma management, DVT/PE monitoring, readmission decisions) | 10% | 1 | 0.10 | NOT INVOLVED | Physical bedside assessment of post-surgical complications — wound dehiscence, anastomotic leaks, fistulae, pelvic abscess. Requires hands-on examination and clinical judgment in complex post-exenteration patients. |
| Patient counseling (diagnosis delivery, treatment options, consent for radical procedures, goals-of-care, palliative transitions) | 10% | 1 | 0.10 | NOT INVOLVED | Delivering a cancer diagnosis, explaining that a pelvic exenteration will result in permanent colostomy and urostomy, navigating patient and family wishes about continuing vs stopping treatment — irreducibly human. Trust and empathy ARE the value. |
| MDT coordination & clinical trial management (tumour board participation, research protocol adherence, cross-specialty liaison) | 5% | 2 | 0.10 | AUGMENTATION | AI assists with care pathway recommendations and trial matching. Surgeon still leads MDT discussions, interprets cross-disciplinary input, and makes treatment decisions. |
| Documentation & administrative (operative notes, clinical letters, coding, MDT minutes) | 10% | 4 | 0.40 | DISPLACEMENT | AI ambient documentation (DAX/Nuance, Epic modules) and AI-driven simplification of surgical reports (GPT-4 for patient education) increasingly automate documentation workflows. Surgeon reviews but AI drives the documentation process. |
| Total | 100% | 1.65 |
Task Resistance Score: 6.00 - 1.65 = 4.35/5.0
Displacement/Augmentation split: 10% displacement, 35% augmentation, 55% not involved.
Reinstatement check (Acemoglu): AI creates new tasks — validating AI-generated surgical planning models against intraoperative reality, interpreting genomic profiling results (BRCA, HRD, MSI) for PARP inhibitor eligibility, coordinating AI-matched clinical trial enrolment, and monitoring novel immunotherapy side effects. The precision oncology revolution is expanding the gynecologic oncologist's scope.
Evidence Score
| Dimension | Score (-2 to 2) | Evidence |
|---|---|---|
| Job Posting Trends | 2 | Active postings on AMN Healthcare, ASCO career centre across major metropolitan areas. ASCO projects oncology demand growing 15% vs 7% supply increase through 2037. Small subspecialty (~2,000 SGO members) with chronic unfilled positions. Half of US counties have zero OB/GYN — gyn-onc coverage even sparser. |
| Company Actions | 2 | Cancer centres and academic medical centres aggressively recruiting with signing bonuses and retention premiums. NCI-designated centres expanding surgical oncology capacity. No facility cutting gynecologic oncology citing AI. SGO workforce reports cite persistent fellowship pipeline constraints. |
| Wage Trends | 2 | Median $496K-$540K, range $484K-$700K+ (SalaryDr, ZipRecruiter Feb 2026). 42% premium for 10+ years experience. Surging above inflation, driven by subspecialty scarcity and cancer treatment complexity. Among highest-compensated physician subspecialties. |
| AI Tool Maturity | 1 | All gynecologic oncology-specific AI tools remain research-stage (MIA3G ovarian risk, ANAFI intraoperative prediction, Leeds L-AI-OS). AI cervical screening (95% accuracy) augments but is screening, not treatment. da Vinci Level 0 autonomy. No production tools for core surgical or chemotherapy management tasks. Anthropic observed exposure 6.85% (SOC 29-1218) — very low. |
| Expert Consensus | 1 | PMC 2025 review: "medical decisions still require a professional's oversight." Broad agreement AI augments diagnostics and planning but cannot perform surgery or manage chemotherapy. Few AI publications for vulvar/surgical applications. ASCO/SGO consensus: augmentation pathway. |
| Total | 8 |
Barrier Assessment
Reframed question: What prevents AI execution even when programmatically possible?
| Barrier | Score (0-2) | Rationale |
|---|---|---|
| Regulatory/Licensing | 2 | MD/DO + 4-year OB/GYN residency + 3-4 year fellowship + ABOG board certification + subspecialty certification + DEA + state medical licence. Among the longest training pipelines in medicine (12+ years post-degree). No regulatory pathway for AI as independent surgical or prescribing practitioner. |
| Physical Presence | 2 | Cannot perform cytoreductive surgery, pelvic exenteration, or radical hysterectomy remotely or via software. Surgeon physically present in operating theatre with hands in the surgical field. Even da Vinci requires surgeon at console in the room. Unstructured tumour anatomy in every case. |
| Union/Collective Bargaining | 0 | Physicians generally not unionized. Some academic centres have physician unions but gyn-onc rarely affected. |
| Liability/Accountability | 2 | OB/GYN carries the highest malpractice premiums in medicine. Gyn-onc adds cancer-specific liability — missed diagnoses, surgical complications from radical procedures (3-5% pelvic exenteration mortality, 30-44% major complication rate), chemotherapy dosing errors. Personal criminal and civil liability for outcomes. |
| Cultural/Ethical | 2 | Patients facing cancer of reproductive organs — involving fertility, sexuality, body image, and mortality — will not accept AI-driven surgical or treatment decisions. Cultural resistance to non-human involvement in women's cancer care is near-absolute. The surgeon-patient relationship through cancer treatment is deeply personal. |
| Total | 8/10 |
AI Growth Correlation Check
Confirmed 0 (Neutral). AI adoption does not create or destroy demand for gynecologic oncologists. Demand is driven by cancer incidence rates — endometrial cancer rising sharply with obesity prevalence, cervical cancer persistent in unscreened/undervaccinated populations, ovarian cancer diagnosis typically at advanced stage requiring complex debulking. The precision oncology revolution (genomic profiling, PARP inhibitors, immunotherapy) increases the complexity and scope of the role without reducing headcount. This is Green (Stable) — the surgical and medical oncology core is unchanged by AI, and daily work transformation is minimal (<20% task time at score 3+).
JobZone Composite Score (AIJRI)
| Input | Value |
|---|---|
| Task Resistance Score | 4.35/5.0 |
| Evidence Modifier | 1.0 + (8 x 0.04) = 1.32 |
| Barrier Modifier | 1.0 + (8 x 0.02) = 1.16 |
| Growth Modifier | 1.0 + (0 x 0.05) = 1.00 |
Raw: 4.35 x 1.32 x 1.16 x 1.00 = 6.6607
JobZone Score: (6.6607 - 0.54) / 7.93 x 100 = 77.2/100
Zone: GREEN (Green >=48, Yellow 25-47, Red <25)
Sub-Label Determination
| Metric | Value |
|---|---|
| % of task time scoring 3+ | 10% (documentation only) |
| AI Growth Correlation | 0 |
| Sub-label | Green (Stable) — <20% task time scores 3+, Growth 0 |
Assessor override: None — formula score accepted. The 77.2 score sits above the parent OB/GYN (68.6) and the parent Oncologist (66.5), reflecting the higher surgical complexity, greater proportion of irreducible surgical time (35% at score 1), and stronger evidence (acute subspecialty shortage). Calibrates well against Pediatric Surgeon (76.7), Neurosurgeon (78.7), and Trauma Surgeon (83.2) — all Green (Stable) surgical specialties with similar structural protections. The Stable sub-label is appropriate: only 10% of task time scores 3+ (documentation), and the core surgical/medical oncology work is not meaningfully transforming due to AI.
Assessor Commentary
Score vs Reality Check
The 77.2 score places gynecologic oncology solidly in Green (Stable), 29.2 points above the zone boundary. Not borderline. This is not barrier-dependent — even stripping all barriers, the task decomposition alone (1.65 weighted total, 55% of work fully beyond AI reach) anchors the role firmly in Green. The score sits appropriately between the parent OB/GYN (68.6, which includes routine obstetrics) and Trauma Surgeon (83.2, which has higher emergency physicality). The dual surgical + medical oncology competency provides redundant protection — AI would need to automate both complex surgery AND chemotherapy management simultaneously to threaten this role.
What the Numbers Don't Capture
- Burnout and workforce sustainability are the existential threat, not AI. Gyn-onc has among the highest burnout rates in surgical oncology — repeated exposure to patient deaths, moral distress around futile surgery, on-call demands, and the emotional weight of managing cancers in reproductive organs. SGO surveys report increasing fellowship recruitment challenges.
- The surgical volume–outcome relationship is a structural moat. Ovarian cancer debulking outcomes correlate strongly with surgeon volume and specialization — patients treated by gynecologic oncologists have significantly better survival than those treated by general surgeons or OB/GYNs. This drives institutional credentialing requirements that cannot be bypassed by AI.
- Endometrial cancer incidence is rising sharply with the obesity epidemic, creating sustained demand growth independent of any AI dynamic. This is a cancer epidemiology tailwind, not a technology trend.
Who Should Worry (and Who Shouldn't)
If you are a fellowship-trained gynecologic oncologist performing debulking surgery, managing chemotherapy regimens, and leading tumour boards — you are among the most AI-resistant physicians in medicine. Your dual surgical-medical competency, extreme training pipeline, and the irreducible complexity of cancer surgery in variable pelvic anatomy make this role decades from automation. Gynecologic oncologists whose practice has shifted primarily to consultative roles — reviewing imaging, writing chemotherapy orders without hands-on surgery — should note that the surgical component is what drives the highest protection. A purely cognitive gyn-onc practice without operating would score lower. The single biggest separator: whether you are physically in the operating theatre performing cytoreductive surgery. If your hands are in the pelvis debulking tumour, you are deeply protected. If your gyn-onc work is primarily screen-based chemotherapy management without surgery, your protection is still strong but materially lower.
What This Means
The role in 2028: Gynecologic oncologists will use AI-augmented preoperative planning with 3D tumour models from CT/MRI, genomic profiling platforms (Tempus, Foundation Medicine) to guide PARP inhibitor and immunotherapy selection, and ambient documentation to reduce operative note burden. The core job — cytoreductive surgery for ovarian cancer, radical hysterectomy, pelvic exenteration, chemotherapy regimen management, and patient counseling through diagnosis, treatment, and end-of-life — remains entirely human. Demand continues to outstrip supply as cancer incidence rises and fellowship pipeline constraints persist.
Survival strategy:
- Maintain high surgical volume and pursue advanced procedural skills (robotic-assisted surgery, HIPEC, ultra-radical procedures) — surgical competency is the strongest protection and the skill AI cannot replicate
- Build genomic literacy: understand companion diagnostics, HRD testing, MSI status, and how precision oncology platforms inform PARP inhibitor and immunotherapy eligibility — this is the fastest-growing knowledge requirement
- Embrace AI documentation and clinical decision support tools to reduce administrative burden — every minute saved on operative notes is a minute gained for the surgical and patient care work that defines the role
Timeline: 20+ years, likely indefinite for operating gynecologic oncologists. Driven by the fundamental impossibility of automating complex cancer surgery in variable pelvic anatomy, the dual surgical-medical competency requirement, and extreme structural barriers (12+ year training pipeline, highest malpractice liability, near-absolute cultural resistance).
